Beaufort Securities Reaffirms “Speculative Buy” Rating for Amryt Pharma PLC (AMYT)
Amryt Pharma PLC (LON:AMYT)‘s stock had its “speculative buy” rating restated by analysts at Beaufort Securities in a research report issued on Tuesday, November 14th, StockTargetPrices.com reports. They presently have a GBX 65 ($0.85) price objective on the stock. Beaufort Securities’ price target indicates a potential upside of 220.99% from the company’s current price.
Separately, Shore Capital cut their target price on Amryt Pharma from GBX 86 ($1.13) to GBX 70 ($0.92) and set a “house stock” rating on the stock in a research note on Thursday, September 21st.
Amryt Pharma (LON:AMYT) traded down GBX 0.12 ($0.00) during trading hours on Tuesday, reaching GBX 20.25 ($0.27). Amryt Pharma has a 1 year low of GBX 13.44 ($0.18) and a 1 year high of GBX 29.50 ($0.39).
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/25/beaufort-securities-reaffirms-speculative-buy-rating-for-amryt-pharma-plc-amyt.html.
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.
Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.